Scott B. Sellinger, MD

Advanced Urology Institute

Tallahassee, Florida

Scott B. Sellinger, MD, FACS, is president of Advanced Urology Institute in Tallahassee, Florida. He has been a partner at Southeastern Urological Center, now a division of Advanced Urology Institute, since 1991. Dr. Sellinger earned his medical degree from the University of Florida in Gainesville, prior to which he received his BS degree in chemistry from Syracuse University in New York. He completed his urology residency at the University of Florida and has lived in Tallahassee for over 32 years.

Dr. Sellinger was president of the Capital Medical Society in 2003 and served as president of the Florida Urological Society in 2005. In 2018, Dr. Sellinger served as president of the Southeastern Section of the American Urological Association (SESAUA). In 2019, he served as president of the American Association of Clinical Urologists (AACU). In addition to his urology specific work, Dr. Sellinger has developed a special interest in risk management and prevention of medical errors and has lectured extensively on this subject. He is also interested in large group practice development and management. For several years, Dr. Sellinger has served on the board of Advanced Urology Institute (AUI) representing his care center in Tallahassee. In January 2021, he became the second president of AUI, now one of the largest independent urology practices in the United States. Dr. Sellinger currently chairs the Advanced Prostate Cancer (APC) committee and oversees seven APC clinics within AUI. Since 2015, he has also served on the Large Urology Group Practice Association (LUGPA) Board of Directors, where he currently serves as President-Elect. At LUGPA, he is proud to represent over 2300 urologists by working to preserve and advance the independent practice of urology.

Talks by Scott B. Sellinger, MD

How to Best Select Doublet vs. Triplet Therapy in MCSPC

Posted by Scott B. Sellinger, MD | Dec 2024

Scott B. Sellinger, MD, FACS, addresses key considerations in deciding between doublet and triplet therapies for metastatic castration-sensitive prostate cancer.

In this 12-minute presentation, Dr. Sellinger highlights the superiority of androgen deprivation therapy (ADT) combined with androgen pathway inhibitors. He discusses evidence from pivotal trials, including TITAN, ARCHES, PEACE-1, and ARASENS, demonstrating that doublet and triplet therapies offer superior survival benefits compared to ADT alone.

Sellinger emphasizes that selecting between doublet and triplet therapy is both an art and a science, balancing clinical guidelines with patient-specific factors such as age, comorbidities, and access to treatment. While higher volume and symptomatic patients might benefit from more intensive triplet therapy, the importance of patient preference, PSA response, and cost considerations is underscored. He suggests that establishing clearer guidelines on doublet versus triplet therapy could help practitioners make more confident decisions for their patients in this nuanced field.

Bone Health and Non-Cardiovascular Side Effects of ADT

Posted by Scott B. Sellinger, MD | May 2024

Scott B. Sellinger, MD, FACS, addresses ADT’s impact on bone health and other non-cardiovascular side effects of the therapy. He begins by noting that men on ADT are at significant risk of bone fracture, and reviewing the mechanisms behind the increased bone loss and fracture risk in these patients.

Dr. Sellinger presents best practices for assessing and treating patients with increased risk of fracture. He discusses lifestyle interventions, vitamin supplements, and other therapies to prevent bone loss.

Dr. Sellinger concludes by touching on non-cardiovascular side effects of ADT. He discusses best practices for combatting declines in mental, physical, and sexual health that result from ADT.

Burning Questions and Controversies in the Management of Advanced Prostate Cancer Patients

Posted by Scott B. Sellinger, MD | Jul 2022

Scott B. Sellinger, MD, President of Advanced Urology Institute and a Partner at Southeastern Urological Center in Tallahassee, Florida, breaks down treatment groups for advanced prostate cancer and details therapeutic options for each, including additional therapeutic options beyond androgen deprivation therapy such as ARIs, APIs, and PARP inhibitors.

Reinforcing Consistent Testosterone Suppression in ADT

Posted by Scott B. Sellinger, MD | Jan 2022

E. David Crawford, MD, Scott B. Sellinger, MD, and Paul R. Sieber, MD, discuss reinforcing consistent testosterone suppression in ADT and the role of triptorelin.

A Value-Based Health Care Model and PCa

Posted by Scott B. Sellinger, MD | Apr 2018

Scott B. Sellinger, MD, FACS, explains how the constantly evolving Medicare Access and CHIP Reauthorization Act (MACRA) affects Medicare payments to urologists, and how urologists can participate in the Merit-based Incentive Payment System (MIPS). He also discusses the Large Urology Group Practice Association’s (LUGPA’s) efforts to develop urology-specific advanced alternative payment models (AMPs).